| Bioactivity | BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC50 of 1.9 μM. BNC375 exhibits good CNS-drug like properties and clinical candidate potential.[1]. | ||||||||||||
| Invitro | BNC375 significantly potentiates the acetylcholine signal without changing the rapid receptor desensitization[1]. | ||||||||||||
| In Vivo | BNC375 (0.003-10.0 mg/kg, administered orally) exhibits the MED of 0.03 mg/kg, and achieves full reversal of the Scopolamine-induced impairment at 1.0 mg/kg in mouse T-maze model. BNC375 exhibits the plasm half-life (t1/2) of 1.2 h[1]. | ||||||||||||
| Name | BNC375 | ||||||||||||
| CAS | 1557240-80-8 | ||||||||||||
| Formula | C19H23ClN2O3S | ||||||||||||
| Molar Mass | 394.92 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Andrew J Harvey, et al. Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs. ACS Med Chem Lett. 2019 Mar 25;10(5):754-760. |
BNC375
CAS: 1557240-80-8 F: C19H23ClN2O3S W: 394.92
BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC50 of 1
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.